Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology
Academic Article
Overview
MeSH Major
Antigens, Tumor-Associated, Carbohydrate
Biomarkers, Tumor
Neoplasms
Positron-Emission Tomography
Radioisotopes
Zirconium
abstract
In this report, a general strategy to supplement some of the shortcomings of otherwise highly useful circulating biomarkers with immunoPET is described. To expedite the clinical validation of this model, a human monoclonal antibody to CA19.9 (a highly visible but partially flawed serum biomarker for several cancers) was radiolabeled and evaluated, and the compelling preclinical evidence suggests that the radiotracer may enhance the fidelity of diagnosis and staging of pancreatic ductal adenocarcinoma, a notoriously occult cancer.
